Analysed SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ) News Sources
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
03-04-2026
yahoo.com
This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset
22-03-2026
fool.com
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding
21-03-2026
fool.com
This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know
21-03-2026
fool.com
This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know
21-03-2026
fool.com
Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish
21-03-2026
fool.com
Is It Time To Reassess Syndax Pharmaceuticals (SNDX) After Its 88.5% One Year Surge?
18-03-2026
yahoo.com
Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment
13-03-2026
fool.com
Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned
13-03-2026
fool.com
What is the current price of SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ)?
The current price of SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ) is $24.23.
SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ) absolute price change since previous trading day?
The absolute price change of SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ) since the previous trading day is $0.42.
SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ) percentage price change since previous trading day?
The percentage price change of SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ) since the previous trading day is 1.764%.
What is the most recent average sentiment score for SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ)?
The most recent average sentiment score for SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ) is 89 out of 100.
What is the most recent average sentiment for SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ)?
The most recent sentiment for SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ) is .
SEC-8K** Filing Available For SYNDAX PHARMACEUTICALS INC (SNDX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.